Observational evaluation of treatments for oropharyngeal carcinoma
Department of Otorhinolaryngology, Eye & ENT Hospital
This study looks at how well different treatments for oropharyngeal cancer work for patients at various stages of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Eye & ENT Hospital of Fudan University Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT05341479 on ClinicalTrials.gov |
What this trial studies
This observational study assesses the effectiveness of various clinical treatments for patients diagnosed with oropharyngeal carcinoma (OPC). It focuses on early and advanced stages of the disease, comparing outcomes based on tumor characteristics and treatment preferences. The study includes interventions such as surgery, radiotherapy, and chemoradiotherapy, following established clinical guidelines. Patient outcomes will be evaluated based on treatment effectiveness, complications, and functional maintenance.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-90 with oropharyngeal carcinoma at any stage (T1-T4) and no severe comorbidities.
Not a fit: Patients with immunodeficiency, active tuberculosis, or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and outcomes for patients with oropharyngeal carcinoma.
How similar studies have performed: Other studies have shown success in evaluating treatment outcomes for oropharyngeal carcinoma, suggesting that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Oropharyngeal cancer: Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate; * T1, T2, T3, and T4 stage. * Age 18 - 90. * Male or female. * Good compliance. * No other severe related diseases that may impact the treatment (such as other tumors, severe heart, lung and central nervous system diseases, etc.). * Negative pregnancy test (for female patients with fertility). * Male patients with fertility and female patients with fertility and pregnancy risk must agree to use contraceptive methods throughout the study period, and continued until at least 6 months after the last dose of cisplatin. Female patients do not have fertility. Female patients with postmenopausal status. Exclusion Criteria: * Patients who have previously been diagnosed with immunodeficiency or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related diseases. * Patients with a known history of active tuberculosis (TB). * Pregnant women or lactating women. * The doctors believes that it is inappropriate for patients to participate in the trial: having, for example, severe acute or chronic medical conditions (including immune colitis, inflammatory bowel disease, non-infectious pneumonia, pulmonary fibrosis) or mental illness (including recent time \[within the past year\] or active suicidal ideation or behavior).
Where this trial is running
Shanghai, Shanghai
- Department of Otorhinolaryngology, Eye & ENT Hospital — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Lei Tao, Dr.
- Email: doctortaolei@163.com
- Phone: +86 2164377134
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.